Sesti G, Bardtrum L, Dagdelen S, et al. - Among candidates (n = 1,012) with T2D uncontrolled on oral antidiabetic drugs (OADs), researchers tested the safety and effectiveness of insulin degludec/liraglutide (IDegLira) vs insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at 26 weeks in the 104-week DUAL VIII durability trial. Study participants were randomized 1:1 to open-label IDegLira or IGlar U100. Weeks 1, 2, 4 and 12, and every three months thereafter, were scheduled to visit. According to results, HbA_1c reductions were higher with IDegLira vs IGlar U100 after 26 weeks, as were the percentage of participants with no weight gain and/or hypoglycaemia attaining HbA_1c < 53 mmol/mol and HbA_1c targets. The rate of hypoglycaemia with IDegLira was 44% lower than with IGlar U100. The results were similar in terms of safety. The authors concluded that more candidates receiving IDegLira than IGlar U100 met treatment targets in a trial resembling clinical practice, supporting the use of IDegLira as initial injectable therapy for people with T2D uncontrolled on OADs and eligible for insulin initiation.